Table 2.

Antifungal activity of hinokitiol against FLC-resistant or FLC-sensitive C. albicans strains.

Strainsa	Characteristics	MICs (µg/mL)
		Hinokitiol	FLC
DAY364	FLC-sensitive strain with homozygous cnb1/cnb1	2	0.5
DSY465	FLC-sensitive strain with homozygous mdr1/mdr1	2	0.5
YEM13	FLC-resistant strain with hyperexpressed MDR1	8	64
YEM15	FLC-resistant strain with hyperexpressed CDR1 and CDR2	2	64
SCMRR1R34MPG2A	FLC-resistant strain with P683S mutation in MRR1	8	128
SCUPC2R14MPG2A	FLC-resistant strain with G648D mutation in UPC2	2	>128
G5	FLC-resistant clinical isolate with G997V mutation in MRR1	8	>128
GU5	FLC-resistant clinical isolate with G980E mutation in TAC1	1	>128
DSY296	FLC-resistant clinical isolate with N977D mutation in TAC1	1	64
DSY1751	FLC-resistant strain with homozygous erg3/erg3 and heterozygous erg11/ERG11	2	>128
28A	FLC-resistant clinical isolate	2	>128
28I	FLC-resistant clinical isolate	2	>128
28D	FLC-resistant clinical isolate	2	>128

^aAll the strains in this Table were C. albicans. DAY364 is a constructed C. albicans strain with deletion of CNB1; DSY654 is a constructed C. albicans strain with deletion of MDR1; YEM13 is a constructed C. albicans strain with hyperexpression of MDR1; YEM15 is a constructed C. albicans strain with hyperexpression of both CDR1 and CDR2; SCMRR1R34MPG2A is a constructed C. albicans strain with a gain-of-function mutation in MRR1; SCUPC2R14MPG2A is a constructed C. albicans strain with a gain-of-function mutation in UPC2; G5 is a FLC-resistant clinical isolate from AIDS patient G with a gain-of-function mutation in MRR1; Gu5 is a FLC-resistant clinical isolate from AIDS patient Gu with a gain-of-function mutation in TAC1. DSY296 is a FLC-resistant clinical isolate with a gain-of-function mutation in of TAC1. DSY1751 is a constructed C. albicans strain with deletion of ERG3 and heterozygous erg11/ERG11. 28A, 28I and 28D are clinical pan-azole-resistant strains isolated from a cancer patient.